Opinion channel feed – Endpoints News

Opinion channel feed

BioRegnum snapshot: Who are the real insiders when it comes to healthcare policy?

9 years ago

Thumbs Up. Thumbs Down: On rookie mistakes, a class action suit and getting past failure

9 years ago

BioRegnum: The fog of M&A. What constitutes a legit buyout ‘scoop’ these days?

9 years ago

Thumbs Up/Thumbs Down: The FDA backs another R&D scheme, Kite shows its speed while Eli Lilly and Astra stumble again

9 years ago

An introduction to the Endpoints 100

9 years ago

Thumbs Up/Thumbs Down: The new buzz in R&D, blockbuster work on a budget and why what’s dead may never die

9 years ago

BioRegnum: What’s the deal with Biogen?

9 years ago

BioRegnum: The miracle drug story that just won’t die

9 years ago

BioRegnum: Another great reason emerges for AstraZeneca to target new biotech deals

9 years ago

Knock it off: Biosimilars are not a 'knockoff' drug

9 years ago

Why we need to lower U.S. regulatory barriers around biosimilar approvals now

9 years ago

Master dealmaker? Medivation CEO David Hung’s overzealous PARP assault falls flat

9 years ago

The Zerhouni rule: “Every company that acquires a platform company kills it.”

9 years ago

These 300(+) Biotech Twitter citizens are the quickest to tweet news

9 years ago

Pluristem uses the preclinical hype gambit to whip up a quickie stock gain

9 years ago

First page Previous page 7 8 910